Celsion Reports Data Safety Monitoring Board Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer
19 juil. 2021 08h00 HE | Celsion CORP
OVATION 2 Study is 50% Enrolled; Excellent R0 Surgical Resection Noted Novel Gene-Mediated Immunotherapy is Safe and Demonstrates an Acceptable Risk/Benefit When Administered Over a Six-Month...